Evidence map›Paper›PMID 32696593›Full record

ArticleJournal of diabetes investigation2021

Different interaction of onset age and duration of type 1 diabetes on the dynamics of autoantibodies to insulinoma-associated antigen-2 and zinc transporter 8.

Eiji Kawasaki, Yoichi Oikawa, Akira Okada, Norio Kanatsuna, Tomoyuki Kawamura, Tadashi Kikuchi, Jungo Terasaki, Junnosuke Miura, Yoshihisa Itoh, Toshiaki Hanafusa

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in Journal of diabetes investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eiji KawasakiDiabetes Center, Shin-Koga Hospital, Kurume, Japan.ORCID https://orcid.org/0000-0001-7434-4744
Yoichi OikawaDepartment of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1524-6751
Akira OkadaOkada Clinic, Fukuoka, Japan.
Norio KanatsunaDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Japan.
Tomoyuki KawamuraDepartment of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan.ORCID https://orcid.org/0000-0002-3593-9910
Tadashi KikuchiCosmic Corporation, Tokyo, Japan.
Jungo TerasakiDepartment of Internal Medicine (I), Osaka Medical College, Takatsuki, Japan.
Junnosuke MiuraDiabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5115-1111
Yoshihisa ItohEiju General Hospital, Tokyo, Japan.
Toshiaki HanafusaSakai City Medical Center, Sakai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AIMS/

introductionThis study aimed to investigate the dynamics associated with autoantibodies to insulinoma-associated antigen-2 (IA-2A) and zinc transporter 8 (ZnT8A) relating to the onset age and disease duration in patients with type 1 diabetes.

methodsUsing bridging-type enzyme-linked immunosorbent assay, IA-2A, ZnT8A and glutamic acid decarboxylase autoantibodies were evaluated in 269 patients with type 1 diabetes (median onset age 18.2 years, range 0.8-86 years; median diabetes duration 7 years, range 0-58 years). We then compared the prevalence of these autoantibodies among the different age groups, along with the duration of diabetes using the Cochran-Armitage trend test and multivariate logistic regression analysis.

resultsThe prevalence of IA-2A, ZnT8A and glutamic acid decarboxylase autoantibodies in patients with duration of ≤3 years was 41.1, 36.7 and 72.2%, respectively, with 80.0% expressing one or more of these autoantibodies. This prevalence declined according to the disease duration (P < 0.005). Both IA-2A and ZnT8A were more frequently observed in younger patients, whereas glutamic acid decarboxylase autoantibodies was more common in older patients. Multivariate logistic regression analysis showed that there was a significant interaction between the onset age and duration of diabetes in patients diagnosed when aged ≤10 years regarding all anti-islet autoantibodies (P < 0.05). However, for patients diagnosed in the middle tertile (aged 11-30 years), the interaction was significant only for ZnT8A, and for those with late-onset diabetes (aged ≥31 years) only for IA-2A.

conclusionsThe current study showed that the rate of disappearance of anti-islet autoantibodies is faster in patients aged ≤10 years, and that even though both proteins are localized in the insulin granule membrane, humoral autoimmunity to IA-2 and ZnT8 differs according to the age of onset.

Indexed as

AdolescentAdultAge of OnsetAutoantibodiesChildChild, PreschoolDiabetes Mellitus, Type 1Glutamate DecarboxylaseHumansInfantMiddle AgedReceptor-Like Protein Tyrosine Phosphatases, Class 8Young AdultZinc Transporter 8AutoantibodiesGlutamate DecarboxylasePTPRN protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 8SLC30A8 protein, humanZinc Transporter 8AgeAutoantibodiesType 1 diabetes

Identifiers

PMID32696593
PMCPMC8015838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.